

# Fifty 1 Labs, Inc.

1505 W 2nd Ave Suite 506  
Vancouver, BC V6J 1H2 Canada  
1 877-505-5006  
www.fifty1labs.com  
ir@fifty1labs.com  
SIC Code: 6199

## Annual Report

For the period ending June 30, 2025 (the "Reporting Period")

### Outstanding Shares

The number of shares outstanding of our Common Stock was:

571,878,600 as of June 30, 2025 (Current Reporting Period Date or More Recent Date)

571,878,600 as of March 31, 2025 (Most Recent Completed Fiscal Year End)

### Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

### Change in Control

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes:  No:

---

<sup>1</sup> "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Currently – Fifty 1 Labs, Inc. – 3/2025 to present  
Formerly – Consumer Automotive Finance, Inc. – 6/2016 to 3/2025  
Formerly – NowAuto Group, Inc. – 7/2015 to 3/2016  
Formerly – NowAuto, Inc. – 8/2004 to 6/2015  
Formerly – Automotive Capital Group, Inc. – 6/2004 to 8/2004  
Formerly – WH Holdings, Inc. – 8/1998 to 6/2004

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Active in the state of Nevada as of August 19, 1998

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

The address(es) of the issuer's principal executive office:

1525 11<sup>th</sup> Avenue, Seattle, WA 98122  
1505 W 2<sup>nd</sup> Ave Suite 506, Vancouver, BC V6J1H2 Canada

The address(es) of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

\_\_\_\_\_

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:  Yes:  If Yes, provide additional details below:

\_\_\_\_\_

**2) Security Information**

Transfer Agent

Name: Pacific Stock Transfer  
Phone: 800-785-7785  
Email: Michelle@pacificstocktransfer.com  
Address: 6725 Via Austi Pkwy Suite 300 Las Vegas, NV 89119

**Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	<u>CAFI</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>210493102</u>	
Par or stated value:	<u>.001</u>	
Total shares authorized:	<u>800,000,000</u>	as of date: <u>6/30/2025</u>
Total shares outstanding:	<u>571,878,600</u>	as of date: <u>6/30/2025</u>
Number of shares in the Public Float <sup>2</sup> :	<u>468,765,751</u>	as of date: <u>6/30/2025</u>
Total number of shareholders of record:	<u>32</u>	as of date: <u>6/30/2025</u>

**Other classes of authorized or outstanding equity securities:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security:	<u>Preferred Series A</u>	
CUSIP (if applicable):		
Par or stated value:	<u>.00001</u>	
Total shares authorized:	<u>3,800,000</u>	as of date: <u>6/30/2025</u>
Total shares outstanding (if applicable):	<u>3,800,000</u>	as of date: <u>6/30/2025</u>
Total number of shareholders of record (if applicable):	<u>1</u>	as of date: <u>6/30/2025</u>

Exact title and class of the security:	<u>Preferred Series B</u>	
CUSIP (if applicable):		
Par or stated value:	<u>.00001</u>	
Total shares authorized:	<u>10,200,000</u>	as of date: <u>6/30/2025</u>
Total shares outstanding (if applicable):	<u>8,037,142</u>	as of date: <u>6/30/2025</u>
Total number of shareholders of record (if applicable):	<u>5</u>	as of date: <u>6/30/2025</u>

**Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

**1. For common equity, describe any dividend, voting and preemption rights.**

Except as otherwise required by law, the holders of Common Stock shall be entitled to one vote per share on all matters upon which holders of shares of Common Stock shall be entitled to vote.

**2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

- a. Preferred A Stock Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any stock ranking junior to the Series A Preferred Stock, the holders of the Series A Preferred Stock shall be entitled to be paid out of the assets of the Company an amount equal to \$1.00 per share or, in the event of an aggregate subscription by a single subscriber for Series A Preferred Stock in excess of \$100,000,

<sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

\$0.997 per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares) (the "Preference Value"), plus all declared but unpaid dividends, for each share of Series A Preferred Stock held by them. After the payment of the full applicable Preference Value of each share of the Series A Preferred Stock as set forth herein, the remaining assets of the Company legally available for distribution, if any, shall be distributed ratably to the holders of the Company's Common Stock. Conversion Formula. At the Conversion Time, each share of Series A Preferred Stock subject to conversion shall be convertible into 30 shares of Common Stock.

- b. Preferred B Stock have the same liquidation rights as the holders of the Company's Common Stock. Series B Preferred Stock shall have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and shall be entitled to notice of any stockholders' meeting in accordance with the bylaws of the Company (as in effect at the time in question) and applicable law, and shall be entitled to vote, together with the holders of Common Stock, with respect to any question upon which holders of Common Stock have the right to vote, except as may be otherwise provided by applicable law. Except as otherwise expressly provided herein or as required by law, the holders of Series B Preferred Stock and the holders of Common Stock and other series of the Company's preferred stock shall vote together as a single class. At the Conversion Time, each share of Series B Preferred Stock subject to conversion shall be convertible into 350 shares of Common Stock

3. Describe any other material rights of common or preferred stockholders.

- a. There are no other material rights of common or preferred shareholders.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

- b. There are no provisions in the issuer's charter or by-laws that would delay, defer or prevent a change in control of the issuer.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>3/31/2023</u> Common: <u>707,660,385</u> Preferred: <u>4,634,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation,	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share)	Were the shares issued at a discount to market	Individual/ Entity Shares were issued to.	Reason for share issuance (e.g. for cash or debt conversion) - OR-	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

	shares returned to treasury)			at issuance	price at the time of issuance? (Yes/No)	*You must disclose the control person(s) for any entities listed.	Nature of Services Provided		
<u>4/25/2023</u>	<u>New Issuance</u>	<u>20,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Branded Legacy Inc. C/O Jermain Strong</u>	<u>Acquisition</u>	<u>Restricted</u>	<u>n/a</u>
<u>7/25/2023</u>	<u>New Issuance</u>	<u>33,334</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Rene Lauritsen</u>	<u>Consulting Agreement</u>	<u>Unrestricted</u>	<u>n/a</u>
<u>1/23/2024</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Covert, LLC Jared Fisher</u>	<u>Consulting Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>2/9/2024</u>	<u>Cancellation</u>	<u>-20,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Branded Legacy Inc. C/O Jermain Strong</u>	<u>Acquisition</u>	<u>Restricted</u>	<u>n/a</u>
<u>2/9/2024</u>	<u>Cancellation</u>	<u>-50,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Jamie Collins</u>	<u>Consulting Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>2/13/2024</u>	<u>New Issuance</u>	<u>68,318,215</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>MN 2019, LLC – Matthew Nicoletti</u>	<u>Convertible Note</u>	<u>Unrestricted</u>	<u>n/a</u>
<u>5/28/2024</u>	<u>New Issuance</u>	<u>27,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Dhamendra Patel</u>	<u>Purchase Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>9/17/2023</u>	<u>New Issuance</u>	<u>3,333,333</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Anthony Nicoletti</u>	<u>Consulting Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>11/21/2024</u>	<u>Cancellation</u>	<u>-200,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>12/11/2024</u>	<u>New Issuance</u>	<u>3,833,333</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>12/20/2024</u>	<u>Cancellation</u>	<u>154,000</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>12/20/2024</u>	<u>New Issuance</u>	<u>53,900,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>1/6/2025</u>	<u>Cancellation</u>	<u>-54,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Brandon Spikes</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>1/6/2025</u>	<u>New Issuance</u>	<u>154,285</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Brandon Spikes</u>	<u>Exchange Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>1/15/2025</u>	<u>New Issuance</u>	<u>59,500,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>1/15/2025</u>	<u>Cancellation</u>	<u>-170,000</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>1/31/2025</u>	<u>New Issuance</u>	<u>63,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>1/31/2025</u>	<u>Cancellation</u>	<u>-180,000</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>2/12/2025</u>	<u>New Issuance</u>	<u>70,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>2/12/2025</u>	<u>Cancellation</u>	<u>-200,000</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>3/4/2025</u>	<u>Cancellation</u>	<u>-246,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Brandon Spikes</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>3/4/2025</u>	<u>New Issuance</u>	<u>702,857</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Brandon Spikes</u>	<u>Exchange Agreement</u>	<u>Restricted</u>	<u>n/a</u>

<u>3/6/2025</u>	<u>New Issuance</u>	<u>52,500,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>3/6/2025</u>	<u>Cancellation</u>	<u>-150,000</u>	<u>Preferred</u>	<u>.00001</u>	<u>No</u>	<u>Jermain Strong</u>	<u>Employment Agreement</u>	<u>Restricted</u>	<u>n/a</u>
<u>3/17/2025</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>.001</u>	<u>No</u>	<u>Genetic Networks – Genaro D’Urso</u>	<u>Acquisition Agreement</u>	<u>Restricted</u>	<u>n/a</u>
Shares Outstanding on Date of This Report: Date <u>6/30/2025</u> Ending Balance Common: <u>571,878,600</u> Preferred: <u>11,837,142</u>									

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_

## B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer’s equity securities:

No:  Yes:  (If yes, you must complete the table below)

<u>Date of Note Issuance</u>	<u>Outstanding Balance (\$)</u>	<u>Principal Amount at Issuance (\$)</u>	<u>Interest Accrued (\$)</u>	<u>Maturity Date</u>	<u>Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)</u>	<u>Name of Noteholder.</u> <u>*You must disclose the control person(s) for any entities listed.</u>	<u>Reason for Issuance (e.g. Loan, Services, etc.)</u>
<u>11/1/2017</u>	<u>55,000</u>	<u>125,000</u>	<u>9,437</u>	<u>11/1/2019</u>	<u>Option to convert to Common Stock at par value</u>	<u>Asher Emma Revocable/Asher Emma has voting/investment control</u>	<u>Loan for Operating Capital</u>
<u>3/28/2020</u>	<u>39,328</u>	<u>50,000</u>	<u>11,314</u>	<u>3/28/2022</u>	<u>Option to convert to Common Stock at .00065</u>	<u>Richard Krey</u>	<u>Loan for Operating Capital</u>
<u>10/23/2023</u>	<u>6,357</u>	<u>5,000</u>	<u>1,357</u>	<u>10/23/2024</u>	<u>Option to convert to Common Stock</u>	<u>Matthew Nicoletti</u>	<u>Loan for Operating Capital</u>
<u>12/29/2023</u>	<u>7,457</u>	<u>6,000</u>	<u>1,457</u>	<u>12/29/2024</u>	<u>Option to convert to Common Stock</u>	<u>Matthew Nicoletti</u>	<u>Loan for Operating Capital</u>
<u>6/17/2024</u>	<u>15,452</u>	<u>13,370</u>	<u>2,082</u>	<u>6/17/2025</u>	<u>Option to convert to Common Stock</u>	<u>Matthew Nicoletti</u>	<u>Loan for Operating Capital</u>
<u>8/1/2024</u>	<u>0</u>	<u>20,000</u>	<u>0</u>	<u>8/1/2026</u>	<u>Option to convert to Common Stock at .0001</u>	<u>Anthony Nicoletti</u>	<u>Loan for Operating Capital</u>
<u>8/2/2024</u>	<u>5,735</u>	<u>5,100</u>	<u>635</u>	<u>8/2/2025</u>	<u>Option to convert to Common Stock</u>	<u>Matthew Nicoletti</u>	<u>Loan for Operating Capital</u>
<u>9/24/2024</u>	<u>120,938</u>	<u>100,000</u>	<u>20,938</u>	<u>9/24/2026</u>	<u>Option to convert to Common Stock at par value</u>	<u>Eduardo Lopes</u>	<u>Loan for Operating Capital</u>
<u>4/30/2025</u>	<u>12,198</u>	<u>11,900</u>	<u>298</u>	<u>4/30/2026</u>	<u>Option to convert to Common Stock</u>	<u>Matthew Nicoletti</u>	<u>Loan for Operating Capital</u>

Use the space below to provide any additional details, including footnotes to the table above:

N/A

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. (Please ensure that these descriptions are updated on the Company's Profile on [www.otcmarkets.com](http://www.otcmarkets.com)).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Fifty 1 Labs, Inc. is a Nevada-based holding company revolutionizing health, wellness, and biotech through AI-driven drug repurposing and functional medicine. Fifty 1 Labs, Inc. operates subsidiaries including Fifty1 AI Labs LLC and 51 Labs LLC, focusing on personalized medicine, sports nutrition, and innovative therapeutics. With Fifty1 AI Labs' cutting-edge AI platform, Fifty 1 Labs, Inc. is poised to lead the \$1.55 trillion biotech market, delivering transformative solutions for patients and shareholders. Fifty 1 Labs wholly owned subsidiary, 51 Labs, LLC, offers a premium line of supplements - including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies - designed to enhance athletic performance, recovery, and overall health.

B. List any subsidiaries, parent company, or affiliated companies.

Fifty1 AI Labs, LLC – AI-driven drug repurposing.

51Labs, LLC – Brand of Sports Supplements.

C. Describe the issuers' principal products or services.

Fifty1 AI Labs LLC is redefining what drug discovery looks like — using AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.

Fifty1 AI Labs harnesses biomedical data and applied machine learning to uncover new uses for existing compounds — reducing risk, accelerating development, and unlocking untapped value in molecules that already work. By focusing on proven therapies with established safety profiles, we shorten the path from insight to impact.

51 Labs, LLC is a health and wellness company that specializes in providing high-quality sports supplements, such as protein powder, creatine, glutamine, pre-workout, BCAA's, and probiotics for athletes and health-conscious individuals. The company was founded with the vision of using carefully formulated products to provide essential nutrients that can help athletes perform at their best.

The company has been launched under the leadership of Brandon Spikes, former NFL, 51 Labs, LLC is confident that their products are made with the highest quality ingredients and will be well-received by their target market.

As a health and wellness company, 51 Labs, LLC aims to promote a healthy lifestyle and empower individuals to reach their fitness goals. The company will continue to innovate and expand its product line to meet the needs of its customers.

#### 5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company multiple locations in the United States and Canada including offices and laboratories.

1525 11<sup>th</sup> Avenue, Seattle, WA 98122

## 6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuers securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Paul Arora</u>	<u>CEO</u>	<u>Toronto, CA</u>	-	-	-	-
<u>Alind Gupta</u>	<u>CTO</u>	<u>Vancouver, CA</u>	-	-	-	-
<u>Nima Sakian</u>	<u>Chief Medical Officer</u>	<u>Vancouver, CA</u>	-	-	-	-
<u>James Orbinski</u>	<u>Senior Scientist Officer</u>	<u>Vancouver, CA</u>	-	-	-	-
<u>Richard Robins</u>	<u>Chief Business Development Advisor</u>	<u>Vancouver, CA</u>	-	-	-	-
<u>Edward Mills</u>	<u>Director</u>	<u>Vancouver, CA</u>	-	-	-	-
<u>Kristian Thorland</u>	<u>Director</u>	<u>Vancouver, CA</u>	-	-	-	-
<u>Robert Clark</u>	<u>Director</u>	<u>Melbourne, FL</u>	-	-	-	-

<u>Brandon Spikes</u>	<u>President, Director</u>	<u>Charlotte, NC</u>	<u>857,142</u>	<u>Preferred B</u>	<u>10.665%</u>	<u>-</u>
<u>Brandon Spikes</u>	<u>President, Director</u>	<u>Charlotte, NC</u>	<u>3,800,000</u>	<u>Preferred A</u>	<u>100%</u>	<u>-</u>
<u>Curtis Young</u>	<u>Director</u>	<u>Shelby, NC</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
<u>Anthony Nicoletti</u>	<u>Non-affiliate</u>	<u>New York, NC</u>	<u>3,333,333</u>	<u>Preferred B</u>	<u>41.474%</u>	<u>-</u>
<u>R&amp;J Management Group</u>	<u>Non-affiliate</u>	<u>1008 Brookmeade Dr Waxhaw,NC 28173</u>	<u>834,000</u>	<u>Preferred B</u>	<u>10.377%</u>	<u>Jamie Collins</u>
<u>Jermain Strong</u>	<u>Non-affiliate</u>	<u>Gastonia, NC</u>	<u>2,979,333</u>	<u>Preferred B</u>	<u>37.07%</u>	<u>-</u>

## 7) Legal/Disciplinary History

A. Identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

N/A

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

N/A

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

N/A

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

N/A

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

N/A

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

### Securities Counsel

Name: John E. Dolkart, Jr.  
Firm: Dolkart Law PC  
Address 1: 100 Pine Street, Suite 1250  
Address 2: San Francisco, CA 94111  
Phone: 415-707-2717  
Email: john@dolkartlaw.com

### Accountant or Auditor

Name: N/A  
Firm: N/A  
Address 1: N/A  
Address 2: N/A  
Phone: N/A  
Email: N/A

### Investor Relations

Name: N/A  
Firm: N/A  
Address 1: N/A  
Address 2: N/A  
Phone: N/A  
Email: N/A

### Other Service Providers

*All other means of Investor Communication:*

Twitter: N/A  
Discord: N/A  
LinkedIn: N/A  
Facebook: N/A  
N/A

### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: N/A  
Firm: N/A

Nature of Services: N/A  
Address 1: N/A  
Address 2: N/A  
Phone: N/A  
Email: N/A

## 9) Financial Statements

A. This Disclosure Statement was prepared by (name of individual):

Name: **Robert Clark**  
Title: **Director**  
Relationship to Issuer: **Director**

B. The following financial statements were prepared in accordance with:

- IFRS  
 U.S. GAAP

C. The following financial statements were prepared by (name of individual)<sup>3</sup>:

Name: **Robert Clark**  
Title: **Director**  
Relationship to Issuer: **Director**

Describe the qualifications of the person or persons who prepared the financial statements:

Robert Clark currently is serving as an Officer for multiple public companies, where he is responsible for overseeing the financial operations and ensuring compliance with regulatory requirements. In this role, he has gained valuable experience in financial reporting, budgeting, and strategic planning.

Overall, he has been dealing with finances for over 10 years and has developed a deep understanding of the accounting and financial principles that are essential for running a successful business.

Provide the following qualifying financial statements:

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

### **Financial Statement Requirements:**

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

---

<sup>3</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

**Fifty1 Labs, Inc.**  
**Consolidated Balance Sheet**  
**Year Ending**  
**30-Jun-25**

Assets	30-Jun-25	31-Mar-25
Current Assets		
Cash and cash equivalents	4,971	3
Total Current Assets	\$ 4,971	\$ 3
Other Assets		
Inventory Assets	1,570	1,570
Total other assets	\$ 1,570	\$ 1,570
Total assets	\$ 6,541	\$ 1,573
Liabilities and stockholder's equity (deficit)		
Current Liabilities		
Convertible notes payable	160,000	160,000
Due to related party	-	-
Unsecured loan for interest	50,642	50,642
Total Current Liabilities	\$ 210,642	\$ 210,642
Total Liabilities	\$ 210,642	\$ 210,642
Stockholder's Equity		
Common stock par value \$0.001 authorized 800,000,000 shares and 571,878,600 shares issued and outstanding as on June 30, 2025	571,878	571,878
Preferred stock par value \$0.00001 authorized 14,000,000 shares and 11,837,142 shares issued and outstanding as on June 30, 2024	117	117
Preferred stock issuable (1,429,000 shares)	14	
Additional paid in capital	5,575,845	5,211,699
Opening Balance Equity		
Accumulated deficit	(6,351,956)	(5,992,764)
Total stockholder's equity (deficit)	(204,101)	(209,069)
Total liabilities and stockholder's equity (deficit)	\$ 6,541	\$ 1,573

**Fifty1 Labs, Inc.**  
**Consolidated Statement of Operations**  
**Year Ending**  
**30-Jun-25**

	30-Jun-25	31-Mar-25
Revenue, Net	\$ -	\$ 101
Cost of Goods Sold	\$ -	\$ 58
Gross Profit	\$ -	\$ 43
Expenses		
General and Administrative	\$ 359,192	\$ 6,356
Total Expenses	\$ 359,192	\$ 6,356
Other income (expense)		
Interest income net	\$ -	\$ -
Other Income	\$ -	\$ -
Total other income	\$ -	\$ -
Net Income (Loss)	\$ (359,192)	\$ (6,313)
Loss Per Common Share	\$ -	\$ -
Weighted Average Common Shares Outstanding	\$ 637,478,600	\$ 637,478,600

**Fifty1 Labs, Inc.**  
**Consolidated Statement of Cash Flows**  
**Year Ending**  
**30-Jun-25**

	30-Jun-25	31-Mar-25
<b>OPERATING ACTIVITIES</b>		
Net Income	\$ (359,192)	\$ (6,313)
Adjustments to reconcile Net Income to Net Cash provided by operations:		
Decrease (Increase) in Accounts Receivable	-	-
Decrease (Increase) in Inventory	-	47
Increase (Decrease) in Accounts Payable	-	-
Total Adjustments to reconcile Net Income to Net Cash provided by operations:	-	-
Net cash provided by operating activities	(359,192)	(6,265)
<b>INVESTING ACTIVITIES</b>		
Purchase of Equipment	-	-
Goodwill	-	-
Net cash provided by investing activities	-	-
<b>FINANCING ACTIVITIES</b>		
Unsecured Loan	-	6,266
Notes Payable	-	5,000
Additional paid in capital	364,146	(534,983)
Common Stock	-	535,000
Preferred Stock	14	(17)
Opening Balance Equity	-	(5,000)
Net cash provided by financing activities	364,160	6,266
Net cash increase for period	4,968	1
Cash at beginning of period	3	2
Cash at end of period	\$ 4,971	\$ 3

**Fifty1 Labs, Inc.**  
**Consolidated Statements of Stockholder's (Deficit)**  
**30-Jun-25**

	<u>Common Stock</u>		<u>Preferred Stock</u>		<u>Preferred Stock Issuable</u>		<u>Additional Paid in Capital</u>	<u>Accumulated Deficit</u>	<u>Total Stockholder's Deficit</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>			
<b>Balance March 31, 2024</b>	<b>735,978,600</b>	<b>735,978</b>	<b>4,667,334</b>	<b>47</b>	<b>4,667,334</b>	<b>47</b>	<b>4,982,834</b>	<b>(5,865,794)</b>	<b>(146,936)</b>
Funds from private investor							1,400		1,400
Issuance	27,000,000	27,000							27,000
Cancelation									-
Net Income								(5,578)	(5,578)
<b>Balance June 30, 2024</b>	<b>762,978,600</b>	<b>762,978</b>	<b>4,667,334</b>	<b>47</b>	<b>-</b>	<b>-</b>	<b>4,984,234</b>	<b>(5,871,372)</b>	<b>(124,114)</b>
Opening Balance Adjustment								19,854	19,854
Funds from private investor							5,100		5,100
Issuance			3,333,333	33			19,966		19,999
Cancelation									-
Net Income								(124,938)	(124,938)
<b>Balance September 30, 2024</b>	<b>762,978,600</b>	<b>762,978</b>	<b>8,000,667</b>	<b>80</b>	<b>-</b>	<b>-</b>	<b>5,009,300</b>	<b>(5,976,456)</b>	<b>(204,098)</b>
Funds from private investor							5,070		5,070
Issuance			3,833,333	38					38
Conversion	53,900,000	53,900	(154,000)	(2)			(53,936)		(38)
Cancelation	(200,000,000)	(200,000)					200,000		-
Net Income								(5,213)	(5,213)
<b>Balance December 31, 2024</b>	<b>616,878,600</b>	<b>616,878</b>	<b>11,680,000</b>	<b>117</b>	<b>-</b>	<b>-</b>	<b>5,160,434</b>	<b>(5,981,669)</b>	<b>(204,240)</b>
Funds from private investor							6,266		6,266
Issuance	10,000,000	10,000	857,142	8			-10000		8
Conversion	245,000,000	245,000	(700,000)	(7)			(245,000)		(7)

Cancelation	(300,000,000)	(300,000)					300,000	(4,784)	(4,784)
Equity Balance Adjustment									
Net Income								(6,313)	(6,313)
<b>Balance March 31, 2025</b>	<b>571,878,600</b>	<b>571,878</b>	<b>11,837,142</b>	<b>117</b>	<b>-</b>	<b>-</b>	<b>5,211,699</b>	<b>(5,992,765)</b>	<b>(209,069)</b>
Funds from private investor							14,146		14,146
Issuance		-							-
Preferred stock issued per sub agreement					1,429,000	14	350,000		350,014
Conversion		-							-
Cancelation		-							-
Equity Balance Adjustment									
Net Income								(359,192)	(359,192)
<b>Balance June 30, 2025</b>	<b>571,878,600</b>	<b>571,878</b>	<b>11,837,142</b>	<b>117</b>	<b>1,429,000</b>	<b>14</b>	<b>5,575,845</b>	<b>(6,351,957)</b>	<b>(204,101)</b>

Fifty1 Labs, Inc.

NOTES TO FINANCIAL STATEMENTS

June 30, 2025

**NOTE 1 - ORGANIZATION AND OPERATIONS**

Fifty 1 Labs, Inc., previously Consumer Automotive Finance, Inc. (the “Company”) was originally incorporated in the State of Nevada on August 19, 1998 as WH Holdings, Inc. In June 2004 the Company changed its name to Automotive Capital Group, Inc. In August 2004 the Company changed its name to NowAuto, Inc. In July 2015 the Company changed its name to NowAuto Group, Inc. and the Company changed its name to Consumer Automotive Finance, Inc. to properly reflect the business direction. In March of 2025 the company completed its name change and ticker symbol change to Fifty 1 Labs, Inc. and FITY.

The Company now owns two subsidiary, Fifty1 AI Labs LLC and 51 Labs, LLC.

Fifty1 AI Labs: is redefining what drug discovery looks like — using AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.

Fifty1 AI Labs harnesses biomedical data and applied machine learning to uncover new uses for existing compounds — reducing risk, accelerating development, and unlocking untapped value in molecules that already work. By focusing on proven therapies with established safety profiles, we shorten the path from insight to impact.

51Labs: 51 Labs is a sports supplement company founded by Brandon Spikes who won two national championships with the Florida Gators and had a long career in the NFL. Mr. Spikes is currently back at the University of Florida where he works on the coaching staff. Mr. Spikes passion for bettering oneself led to the development of 51labs and it's great sports nutrition products used by your average gym going to professional athletes.

The Company, in April of 2023 acquired H2O and Solar Energy Solutions.

H2O and Solar Energy Solutions is a provider of water purification and solar energy systems based in central Florida. H2O and Solar Energy Solutions is a provider of water purification and solar energy systems based in central Florida, with over \$430,000 in revenue generated in 2022. H2O and Solar Energy Solutions provide customized solutions for residential and commercial customers, offering free quotations and home testing to ensure customer satisfaction. With a strong focus on expanding its sales team, H2O and Solar Energy Solutions aims to generate over One Million Dollars (\$1,000,000) in revenue in 2023.

In September of 2023, the Company spun off H2O and Solar Energy Solutions, which is now a private company.

On August 1, 2024 the board of directors approved a resolution to update the series B preferred shares to reflect the following:

Conversion Formula. At the Conversion Time, each share of Series B Preferred Stock subject to conversion shall be convertible into 350 shares of Common Stock (the “Series B Preferred Stock Conversion Formula”). The Series B Preferred Stock Conversion Formula shall be subject to adjustment pursuant to Section 6 from time to time. Following each adjustment, such adjusted Series B Preferred Stock Conversion Formula shall remain in effect until a further adjustment hereunder.

In March of 2023, the Company spun off Drago Knives, LLC, The Quickness, and Astound, which are now private companies.

**NOTE 2 – GOING CONCERN**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

While the Company is attempting to commence operations and generate revenues, the Company's cash position may not be significant enough to support the Company's daily operations. Management intends to raise additional funds by way of a public or private offering. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company's ability to further implement its business plan and generate revenues.

### **NOTE 3 – STOCKHOLDERS' EQUITY**

#### Shares authorized

The Company is authorized to issue 800,000,000 shares of common stock with a par value of \$0.001 per share.

#### Shares issued

On August 10, 2018, the Company issued 5,000,000 shares of common stock to Nicholas Konopka, Officer of the company for share based compensation.

On August 10, 2018, the Company issued 9,000,000 shares of common stock to Paige Tolson, Officer of the company for share based compensation.

On August 10, 2018, the Company issued 5,000,000 shares of common stock to Steve Primak Ttee, Officer of the company for share based compensation.

During the quarter ended September 30, 2018, the Company issued 712,500 shares of common stock for services for the amount of \$71,250.

During the quarter ended September 30, 2018, the Company issued 502,500 shares of common stock for settlement of convertible note payable of \$70,000 and record a gain on settlement of debt of \$19,750.

During the year ended June 30, 2021, no shares were issued.

As of June 30, 2021, and June 30, 2020, the outstanding common stock is 121,910,385 and 121,910,385 shares, respectively.

On November 4, 2022 Brandon Spikes was issued 300,000,000 common shares for his employment agreement.

On December 9, 2022 Jermain Strong was issued 250,000,000 common shares for his employment agreement.

On April 21, 2023 Branded Legacy Inc. C/O Jermain Strong was issued 20,000,000 common shares for the acquisition of H2O and Solar Energy Solutions Inc.

On January 23, 2024 10,000,000 common shares were issued to Covert, LLC per a consulting agreement.

On February 9<sup>th</sup>, 2024 Jermain Strong and Jamie Collins retired 20,000,000 and retired 50,000,000 common shares, respectively.

On October 10, 2023, Jamie Collins entered into an exchange agreement with the company to exchange his 50,000,000 common shares for 833,333 shares of series B preferred stock.

On February 13, 2024 68,318,215 common shares were issued to MN2019, LLC per consulting agreement.

On May 28, 2024 27,000,000 common shares were issued to Dhamendra Patel for the purchase of assets of two kava bars in Florida. The transaction is currently in dispute as Dhamendra Patel has not honored his portion of the agreement.

On August 1, 2024, Jermain Strong entered into an exchange agreement with the company to exchange his 200,000,000 common shares for 3,833,333 shares of series B preferred stock.

On September 17, 2024 3,333,333 series B preferred shares were issued to Anthony Nicoletti to pay off \$20,000 Note.

On March 3, 2025, Brandon Spikes entered into an exchange agreement with the company to exchange his 246,000,000 common shares for 702,857 shares of series B preferred stock.

On June 9, 2025, MTEK Holdings entered into a Subscription Agreement where it purchased 1,429,000 shares of preferred B stock for \$350,000. The 1,429,000 have not yet been issued to MTEK Holdings and can be issued at any time.

#### **NOTE 4 – CONVERTIBLE NOTES PAYABLE**

During the year ended June 30, 2018, the Company received convertible notes payable of \$125,000 for various operating expenses. The note is unsecured, non-interest bearing and it can be convertible in stock. The note is due upon 2 years.

During the quarter ended September 30, 2018, the Company issued 502,000 shares of common stock for settlement of convertible note payable of \$70,000 and record a gain on settlement of debt of \$19,750. (Refer Note 3)

As of June 30, 2023, and June 30, 2022, convertible note outstanding is \$55,000 and 55,000, respectively.

On October 23, 2023, the Company received convertible notes payable to \$,000 for various operating expenses from Matthew Nicoletti. The note is unsecured with annual interest rate of 16.0% and it can be convertible in stock. The note is due upon 1 year.

On December 29, 2023, the Company received convertible notes payable to \$6,000 for various operating expenses from Matthew Nicoletti. The note is unsecured with annual interest rate of 16.0% and it can be convertible in stock. The note is due upon 1 year.

On June 17, 2024, the Company received convertible notes payable to \$13,370 for various operating expenses from Matthew Nicoletti. The note is unsecured with annual interest rate of 16.0% and it can be convertible in stock. The note is due upon 1 year.

On August 1, 2024, the Company received convertible notes payable of \$20,000 for various operating expenses from Anthony Nicoletti. The note was paid back on September 17, 2024 in the way of 3,333,333 series B preferred shares.

On August 2, 2024, the Company received convertible notes payable to \$5,100 for various operating expenses from Matthew Nicoletti. The note is unsecured with annual interest rate of 16.0% and it can be convertible in stock. The note is due upon 1 year.

On September 24, 2024, the Company received convertible notes payable of \$100,000 for various operating expenses from Eduardo Lopes. The note is unsecured with annual interest rate of 50.0% and it can be convertible in stock. The note is due upon 2 years.

On April 30, 2025, the Company received convertible notes payable to \$11,900 for various operating expenses from Matthew Nicoletti. The note is unsecured with annual interest rate of 16.0% and it can be convertible in stock. The note is due upon 1 year.

#### **NOTE 5 – RELATED PARTY TRANSACTIONS**

##### *Due from related party*

During the year ended June 30, 2018, the Company advanced \$6,500 to Nicholas Konopka, Director of the company. These loans are unsecured, non-interest bearing and due on demand. During the year ended June 30, 2018, Nicholas

Konopka, director of the company repaid \$100 to the Company.

During the six months period ended December 31, 2018, net advances of Nicholas Konopka, Director of the company of \$6,400 regrouped to due to related party.

During the year ended June 30, 2019, the Company received \$6,400 from the director of the company. As of June 30, 2019, and 2018, due from Nicholas Konopka, Director of the company is \$18,521 and \$24,921 respectively.

As of June 30, 2023, and June 30, 2022, due from director is \$18,521 and \$24,921 respectively.

#### Due to related party

During the year ended June 30, 2018, the Company received \$1,405 from Nicholas Konopka, Director of the company for operating expenses. These loans are unsecured, non-interest bearing and due on demand. As of June 30, 2018, due to Nicholas Konopka, Director is \$3,105

During the year ended June 30, 2019, the Company received \$15,700 from Nicholas Konopka, Director of the company for operating expenses and the Company repaid \$11,625 to him. These loans are unsecured, non-interest bearing and due on demand. As of June 30, 2019, due to Nicholas Konopka, Director is \$7,180

During the three months ended December 31, 2019, the Company repaid \$6,771 to Nicholas Konopka Director.

During the three months ended March 31, 2020, the Company received \$3,500 for operating expenses. These loans are unsecured, non-interest bearing and due on demand.

During the three months ended September 30, 2020, the company received \$3,000 from Nicholas Konopka, Director of the company for Annual OTC renewal fees and the company repaid \$3,000 to him. These loans are unsecured, non-interest bearing and due on demand.

As of June 30, 2023, and June 30, 2022, due to Nicholas Konopka, Director of the company is \$4,909 and \$4,909 respectively.

#### Share based compensation

On August 10, 2018, the Company issued 5,000,000 shares of common stock to Nicholas Konopka, Officer of the company for share based compensation.

On August 10, 2018, the Company issued 9,000,000 shares of common stock to Paige Tolson, Officer of the company for share based compensation.

On August 10, 2018, the Company issued 5,000,000 shares of common stock to Steve Primack, Officer of the company for share based compensation.

#### **NOTE 6 – UNSECURED LOAN FOR INTEREST**

During the month of April 2020, an amount of \$50,000 was received towards unsecured loan. This loan bears an interest rate of 7.5% per year and due on demand. This loan was to Richard Krey. Each Convertible Note plus accrued interest can be converted into common shares at any time before or after the Maturity Date by the Note Holder at a Conversion Price of .00065. And in the event of a default each Convertible Note plus accrued interest can be converted into common shares at any time after the default date by the Note Holder at the same Conversion Price. Conversion rights under this note cannot and will not be diluted by reverse splits of common stock.

#### **NOTE 7 – SUBSEQUENT EVENTS**

On July 12, 2023 Consumer Automotive Finance, Inc. (OTCPK: CAFI), announced it has appointed a new CEO, Robert Clark, to lead its efforts in bringing new and exciting brands to market. Robert Clark, is a seasoned CEO and has great experience in running companies focused on Consumer Package Goods (CPGs).

On July 8, 2025, Fifty1 Labs, Inc. announced the acquisition of Fifty1 AI Labs and Fifty1 Labs leadership team, blended of scientific excellence, operational expertise, and strategic foresight, propelling the Company toward its ambitious goals. Key members include:

Paul Arora, Chief Executive Officer: A biotech veteran, Dr. Arora drives FITY's strategic vision, overseeing acquisitions, R&D integration, and execution of the Game Plan's aggressive timelines.

James Orbinski, Senior Scientist: A physician and global health authority who received the 1999 Nobel Peace Prize on behalf of Medicines Sans Frontiers (Doctors without Borders). Dr. Orbinski brings three decades of experience in humanitarian medicine and strategic leadership. Former International President of Médecins Sans Frontières and Founder of Drugs for Neglected Diseases Initiative (DNDi), Dr. Orbinski enhances operational execution across FITY and Fifty1 AI Labs LLC, aligning global health insights with proven experience developing new and repurposed medicines for large markets, globally.

Nima Sakian, Chief Medical Officer: A serial entrepreneur and veteran consulting physician, Dr. Sakian drives FITY's vision, identifying acquisitions with aggressive execution on market targeting and drug discovery efforts.

Richard Robins, Chief Business Development Advisor: Mr. Robins' expertise in securing high-value partnerships, including large enterprise collaborations, fuels FITY's growth in the \$1.55 trillion biotech market (Grand View Research).

Alind Gupta, Chief Technology Officer: An expert in machine learning and causal AI, Dr. Gupta leads the development of Fifty1 AI Labs' AI platform, accelerating drug repurposing and data-driven innovation.

Professors Edward Mills, Glenn Sammis, Kristian Thorlund (as Scientific Advisors): These distinguished academic scientists, with decades of expertise in pharmacology, clinical research, and data science, guide FITY's R&D toward transformative discoveries.

Louis Dron, Strategic Advisor: Mr. Dron's strategic acumen strengthens FITY's market positioning and investor relations, critical for uplisting and shareholder value creation.

Brandon Spikes, Director: A former NFL linebacker and seasoned entrepreneur, Spikes leads 51 LLC, FITY's sports and wellness division, developing AI-informed supplements to capture a share of the \$45 billion sports nutrition market (Allied Market Research). His market influence and business savvy amplify FITY's consumer reach.

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Robert Clark certify that:

1. I have reviewed this Disclosure Statement for Fifty 1 Labs, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under

which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

8/27/2025

/s/Robert Clark

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, Robert Clark certify that:

1. I have reviewed this Disclosure Statement for Fifty 1 Labs, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

8/27/2025

/s/Robert Clark

(Digital Signatures should appear as "/s/ [OFFICER NAME]")